---
title: "Nelfinavir enhances cisplatin-induced immunogenic cell death in ovarian cancer cells"
id: "biorxiv-6-combined-nelfinavir-and-cisplatin-treatment-promotes-inflammatory-signaling-and"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-6-combined-nelfinavir-and-cisplatin-treatment-promotes-inflammatory-signaling-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1?rss=1"
published_at: "2026-11-18T09:20:07.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nelfinavir enhances cisplatin-induced immunogenic cell death in ovarian cancer cells
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-6-combined-nelfinavir-and-cisplatin-treatment-promotes-inflammatory-signaling-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1?rss=1)
- **Published At:** 2026-11-18T09:20:07.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators treated ovarian cancer cells with **cisplatin (CDDP)**, the HIV protease inhibitor **nelfinavir (NFV)**, or both and performed RNA sequencing to compare pathway activation. - Data indicated enrichment of interferon-associated, cytoplasmic DNA sensing, inflammatory chemokine, and antigen-presentation pathways after treatments that included NFV; the combination produced larger signals than single agents in these readouts. - NFV alone and the NFV+CDDP combination reduced mature Lamin A protein levels, which correlated with increased extranuclear double-stranded DNA accumulation in treated cells. - Cytosolic fractionation plus droplet digital PCR detected elevated cytosolic **TP53** DNA, particularly after combined NFV and CDDP exposure, implicating nuclear envelope compromise and DNA leakage. - The study team observed increased phosphorylation of **STING** and **TBK1** after combined treatment, consistent with engagement of the **cGAS–STING–TBK1** signaling axis in these cells. - Release of inflammatory and immunogenic cell death (ICD)–associated mediators rose with combination therapy; measured factors included **HMGB1**, **IL18**, and **IFNbeta**, according to the authors. - In an in vivo vaccination experiment, mice immunized with ID8 cells killed by CDDP+NFV showed reduced tumor incidence and burden after live ID8 challenge; freeze-thaw necrotic cells did not confer similar protection. - The authors concluded that NFV enhances the immunogenic consequences of CDDP-induced tumor cell death and proposed further investigation of NFV as a repurposed partner for platinum-based chemotherapy and possible combinations with immunotherapy. - The preprint notes limitations inherent to the reported work (preclinical cellular assays and a murine vaccination model) and calls for additional studies; specific clinical dosing, toxicity, and trial-related details were not reported in the source.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=XVitYw7BL6cV4MRZKkw_BLLUwWhaWJ472ZKTCRjLRCI-1794993654.0331724-1.2.1.1-Ut683lbPhT.ls49zZgVE9SuYTcIXAe4d42qxugQ9N1hrOxLlZkWsgjeQuhLSvLmv) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Combined nelfinavir and cisplatin treatment promotes inflammatory signaling and immunogenic cell death in ovarian cancer cells [ View ORCID Profile](http://orcid.org/0009-0003-7272-2141)Benjamin Forgie, [ View ORCID Profile](http://orcid.org/0000-0003-4970-0799)Sarah Ferrier, Alicia A Goyeneche, [ View ORCID Profile](http://orcid.org/0000-0002-4312-5394)Alexandra Bartolomucci, Desiree Marmo, [ View ORCID Profile](http://orcid.org/0009-0005-2098-6561)Rewati Prakash, Abu SM Noman, Edith Zorychta, [ View ORCID Profile](http://orcid.org/0000-0001-8605-5472)Lucy Gilbert, [ View ORCID Profile](http://orcid.org/0000-0002-2184-2157)Julia V Burnier, [ View ORCID Profile](http://orcid.org/0000-0003-1070-3538)Carlos M Telleria doi: https://doi.org/10.64898/2026.11.16.767109 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Benjamin Forgie 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2BForgie%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Forgie%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABenjamin%2BForgie%2B) * [ORCID record for Benjamin Forgie](http://orcid.org/0009-0003-7272-2141 "Open in new tab") Sarah Ferrier 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2BFerrier%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Ferrier%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ASarah%2BFerrier%2B) * [ORCID record for Sarah Ferrier](http://orcid.org/0000-0003-4970-0799 "Open in new tab") Alicia A Goyeneche 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alicia%2BA%2BGoyeneche%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Goyeneche%20AA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAlicia%2BA%2BGoyeneche%2B) Alexandra Bartolomucci 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alexandra%2BBartolomucci%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Bartolomucci%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAlexandra%2BBartolomucci%2B) * [ORCID record for Alexandra Bartolomucci](http://orcid.org/0000-0002-4312-5394 "Open in new tab") Desiree Marmo 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Desiree%2BMarmo%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Marmo%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ADesiree%2BMarmo%2B) Rewati Prakash 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rewati%2BPrakash%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Prakash%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ARewati%2BPrakash%2B) * [ORCID record for Rewati Prakash](http://orcid.org/0009-0005-2098-6561 "Open in new tab") Abu SM Noman 2 Chittagong University, Bangladesh * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abu%2BSM%2BNoman%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Noman%20AS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAbu%2BSM%2BNoman%2B) Edith Zorychta 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Edith%2BZorychta%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Zorychta%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AEdith%2BZorychta%2B) Lucy Gilbert 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lucy%2BGilbert%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Gilbert%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ALucy%2BGilbert%2B) * [ORCID record for Lucy Gilbert](http://orcid.org/0000-0001-8605-5472 "Open in new tab") Julia V Burnier 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julia%2BV%2BBurnier%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Burnier%20JV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJulia%2BV%2BBurnier%2B) * [ORCID record for Julia V Burnier](http://orcid.org/0000-0002-2184-2157 "Open in new tab") Carlos M Telleria 1 McGill University; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Carlos%2BM%2BTelleria%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Telleria%20CM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ACarlos%2BM%2BTelleria%2B) * [ORCID record for Carlos M Telleria](http://orcid.org/0000-0003-1070-3538 "Open in new tab") * For correspondence: carlos.telleria@mcgill.ca * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5972357/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5972357/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5972357/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5972357/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Platinum (Pt) based chemotherapy remains central to ovarian cancer (OC) treatment, but recurrent disease frequently develops Pt resistance and responds poorly to immune checkpoint inhibitors. Immunogenic cell death (ICD) links tumor cell killing to antitumor immunity; however, cisplatin (CDDP), widely used in OC, is an incomplete ICD inducer. We previously demonstrated that the HIV protease inhibitor nelfinavir (NFV) enhances CDDP induced OC cell death and promotes a lytic, pyroptosis associated phenotype. Here, we investigated whether NFV enhances the immunogenic consequences of CDDP treatment. RNA seq analysis of OC cells treated with CDDP, NFV, or their combination revealed enrichment of interferon (IFN) associated, cytoplasmic DNA sensing, inflammatory chemokine, and antigen presentation pathways following NFV containing treatments. NFV alone and CDDP plus NFV reduced mature Lamin A abundance and increased extranuclear double stranded DNA accumulation. Cytosolic fractionation and droplet digital PCR demonstrated increased cytosolic TP53 DNA, particularly following combined treatment. CDDP plus NFV increased STING and TBK1 phosphorylation, supporting engagement of the cGAS STING TBK1 signaling pathway. The combination enhanced release of inflammatory and ICD associated mediators, including HMGB1, IL18, and IFNbeta. Importantly, vaccination with CDDP plus NFV-treated murine ID8 OC cells protected immunocompetent female mice against subsequent live ID8 cell challenge, reducing tumor incidence and burden. In contrast, ID8 cells killed by freeze thaw-induced accidental necrosis provided no comparable protection. Collectively, these findings indicate that NFV enhances the immunogenic consequences of CDDP induced OC cell death, potentially involving cytoplasmic DNA accumulation and STING TBK1 signaling, and promotes protective antitumor immunity in vivo. These results support further investigation of NFV as a repurposed partner for Pt based chemotherapy and its potential combination with immunotherapy in OC. ### Competing Interest Statement The authors have declared no competing interest. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.1101/2025.10.27.684937v2 "A Bioinformatically Identified 5-SNP Streak in the ARMS2 Promoter Region Links to AMD Through Altered c-ABL Binding and Transcriptional Regulation")[Next ](https://www.biorxiv.org/content/10.64898/2026.11.16.766994v1 "Genomic and phenotypic characterisation of Penicillium melinii, a plant growth-promoting root endophyte that remains effective under salt stress") Posted November 18, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.16.767109v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/18/2026.11.16.767109.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More In
## Related Clinical Research

- [HPV oncogenes shift DNA crosslink repair toward a PRIMPOL-dependent vulnerability](https://medichelpline.com/clinical-feed/biorxiv-6-hpv-oncogenes-rewire-dna-crosslink-repair-to-create-a-primpol-dependent.md)
- [SRSF1 controls transcription and alternative splicing to alter p53 signaling and genome maintenance](https://medichelpline.com/clinical-feed/biorxiv-4-srsf1-coordinates-transcription-and-alternative-splicing-to-modulate-p53-and.md)
- [SLFN11 as a biomarker of cisplatin sensitivity in pediatric solid tumors](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-slfn11-enhances-cisplatin-sensitivity-in-pediatric-cancer-via-activation-of.md)
- [High-fat Diets Reprogram Intestinal Stem Cells and May Raise Colon Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fat-diets-leave-memory-in-gut-stem-cells-that-may-fuel-colon-cancer.md)
- [Camupepimut KRAS Vaccine Induces Strong Immune Responses in Phase 2 Pancreatic Cancer Trial](https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.